NewAmsterdam Pharma Company N.V.
- NAMS
- NASDAQ
- Biotechnology
- Cardiometabolic Therapies
- CETP Inhibitor (Obicetrapib)
$19.83
Today −3.83%Quote Oct 16, 2026, 08:00 PM UTC
−9.58%over the last month
Max drawdown −18.5%From 1-month high −18.5%3 months −33.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$2.32B
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$51.33
+158.9% from here
Floor
$19.51
1.6% below price
Where the price sits
10 analysts
Analyst range, low to high
$45.00$58.00
- Price $19.83
- Resistance $20.55
- Consensus $51.33
The price is just above its floor. Analysts' average target sits about 159% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NAMSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
100